Zobrazeno 1 - 10
of 18
pro vyhledávání: ''
Autor:
Xavier Leleu, Zandra Klippel, David S. Siegel, Maria-Victoria Mateos, Meletios A. Dimopoulos, Hang Quach, Ola Landgren, Saad Z. Usmani, Katja Weisel, Anita Zahlten-Kumeli, Hui Yang
Publikováno v:
The Lancet. 396:186-197
Summary Background Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in combination with daratumumab has shown substantial efficacy wit
Autor:
Syed A. Hussain, Nicholas J. Vogelzang, Margitta Retz, Xiaodong Shen, Yohann Loriot, Ugo De Giorgi, Alain Ravaud, Marjorie C. Green, Thomas Powles, Sanjeev Mariathasan, Na Cui, Gwenaelle Gravis, Aristotelis Bamias, Priti S. Hegde, Daniel Castellano, Romain Banchereau, Stéphane Oudard, Edward E. Kadel, Ignacio Duran, Aude Flechon, Christina Louise Derleth, Toshimi Takano, Ning Leng, Michiel S. van der Heijden
Publikováno v:
The Lancet. 391:748-757
Summary Background Few options exist for patients with locally advanced or metastatic urothelial carcinoma after progression with platinum-based chemotherapy. We aimed to assess the safety and efficacy of atezolizumab (anti-programmed death-ligand 1
Autor:
Bruno Scherrer, Victor Kande Betu Ku Mesu, Crispin Lumbala, Olaf Valverde Mordt, Nathalie Strub-Wourgaft, Wilfried Mutombo Kalonji, Séverine Blesson, Willy Kuziena, Jean Pierre Fina Lubaki, Steven Lumeya Vuvu, Pathou Nganzobo Ngima, Augustin Kasongo Bonama, François Simon, Lewis Kaninda Badibabi, Jean Louis Lumaliza Solomo, Medard Ilunga, Sonja C. Bernhard, Francis Regongbenga Dama, Josué Amici Heradi, Guylain Mandula, Papy Kavunga Lukula, Clélia Bardonneau, Hélène Mahenzi Mbembo, Digas Ngolo Tete, Sophie Delhomme, Antoine Tarral
Publikováno v:
The Lancet. 391:144-154
Summary Background Few therapeutic options are available to treat the late-stage of human African trypanosomiasis, a neglected tropical disease, caused by Trypanosoma brucei gambiense (g-HAT). The firstline treatment is a combination therapy of oral
Autor:
Pál Czobor, W. Wolfgang Fleischhacker, Suresh Durgam, Marc Debelle, Ágota Barabássy, István Bitter, Balázs Szatmári, E. Szalai, Judit Harsányi, Stephen R. Marder, István Laszlovszky, György Németh
Publikováno v:
The Lancet. 389:1103-1113
Summary Background Although predominant negative symptoms of schizophrenia can be severe enough to cause persistent impairment, effective treatment options are lacking. We aimed to assess the new generation antipsychotic cariprazine in adult patients
Autor:
Viktoria Werkström, Eugene R. Bleecker, Marek Lommatzsch, Magnus Aurivillius, Stephanie Sproule, Mitchell Goldman, Gary T Ferguson, Geoffrey Gilmartin, Ken Ohta, Stephanie Korn, Peter Barker, Parameswaran Nair, William W. Busse, J. Mark FitzGerald
Publikováno v:
The Lancet. 388:2128-2141
Summary Background Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We aimed to assess the efficacy and safety of benralizumab as a
Autor:
Fritz Offner, Sebastian Grosicki, Iestyn Dixon, Panagiotis Panagiotidis, Anna Schuh, Chai-Ni Chang, Peter Hillmen, Andrew R. Pettitt, K Govind Babu, Eva Kimby, Tadeusz Robak, Michael Doubek, Marco Montillo, Jodi L Carey, Steen Lisby, Thomas E. Boyd, Janusz Kloczko, Ira Gupta, Ann Janssens, Oliver Wright, Astrid McKeown
Publikováno v:
The Lancet. 385:1873-1883
Treatment for patients with chronic lymphocytic leukaemia who are elderly or who have comorbidities is challenging because fludarabine-based chemoimmunotherapies are mostly not suitable. Chlorambucil remains the standard of care in many countries. We
Autor:
Chris Twelves, Jantien Wanders, David Loesch, Alexey Manikas, Joyce O'Shaughnessy, Denis Mir, Joanne L. Blum, Linda T. Vahdat, Fatima Cardoso, Han Koh, Katarina Petrakova, Seth Seegobin, Javier Cortes, Nicole Meneses, Vladimir Vladimirov, Philippe Bougnoux, Corina E. Dutcus, Philippe Chollet, Véronique Diéras, Thierry Delozier
Publikováno v:
The Lancet. 377:914-923
Summary Background Treatments with survival benefit are greatly needed for women with heavily pretreated metastatic breast cancer. Eribulin mesilate is a non-taxane microtubule dynamics inhibitor with a novel mode of action. We aimed to compare overa
Autor:
Antoinette K, Tshefu, Oumar, Gaye, Kassoum, Kayentao, Ricardo, Thompson, Kirana M, Bhatt, Sanie S S, Sesay, Dorina G, Bustos, Emiliana, Tjitra, George, Bedu-Addo, Isabelle, Borghini-Fuhrer, Stephan, Duparc, Chang Sik, Shin, Lawrence, Fleckenstein, Arnaud, Demange
Publikováno v:
The Lancet. 375:1457-1467
Summary Background There is a need for new artemisinin-based combination therapies that are convenient, effective, and safe. We compared the efficacy and safety of pyronaridine-artesunate with that of artemether-lumefantrine for treatment of uncompli
Autor:
Alex Coutinho, Cheryl A. Liechty, Jonathan Mermin, John R. Lule, Willy Were, Peter Solberg, Paul J. Weidle, Ray L. Ransom, Robert Downing, John Paul Ekwaru
Publikováno v:
The Lancet. 367:1256-1261
Summary Background HIV-1 and malaria are common infections in Africa, and cause substantial morbidity and mortality. HIV infection has been associated with an increased incidence of malaria, and more severe disease. Our aim was to assess the effect o
Autor:
Karen I. Barnes, Francesca Little, H Mcllleron, James Mwenechanya, Madalitso Tembo, M Gomes, Malcolm E. Molyneux, Peter I. Folb, I Ribeiro
Publikováno v:
The Lancet. 363:1598-1605
Many patients with malaria of increasing severity cannot take medicines orally, and delay in injectable treatment can be fatal. We aimed to assess the reliability of absorption, antimalarial efficacy, and tolerability of a single rectal dose of artes